AFT Pharmaceuticals Ltd (ASX: AFP) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


AFT Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $296.77 million
P/E Ratio 20.52
Dividend Yield 0.35%
Shares Outstanding 104.87 million
Earnings per share 0.104
Dividend per share 0.01
Year To Date Return -12.62%
Earnings Yield 4.87%
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • AFT Pharmaceuticals Ltd (ASX: AFP)
    Latest News

    A doctor looks unsure, indicating share price uncertainty for ASX medical companies
    Healthcare Shares

    What's with the AFT Pharmaceuticals (ASX:AFP) share price today?

    The AFT Pharmaceuticals (ASX: AFP) share price is still in the starting blocks this morning after the company released a…

    Read more »

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Healthcare Shares

    Why the AFT Pharmaceuticals (ASX:AFP) share price is in focus

    The AFT Pharmaceuticals (ASX: AFP) share price is one to watch today after the company signed a new US licensing…

    Read more »

    Share Market News

    Why the AFP Pharmaceuticals (ASX:AFP) share price is marching higher

    The AFP Pharmaceuticals Ltd (ASX: AFP) share price is up 3.2% today after announcing a raft of agreements and a…

    Read more »

    a woman
    Coronavirus News

    Coronavirus: ASX pharmacy networks report surge in demand

    Australian pharmacies are looking to follow in the footsteps of supermarkets, with panic-buying due to the coronavirus crisis causing a…

    Read more »

    a woman
    Coronavirus News

    Are ASX pharmaceutical shares a bargain buy right now?

    Given the recent surge in demand, ASX pharmaceutical companies could follow the supermarkets and lock in record sales figures. So,…

    Read more »

    a woman
    Share Gainers

    Why the AFT Pharmaceuticals share price is up 55% since April

    The AFT Pharmaceuticals Ltd (ASX: AFP) share price is up 55% since April 23 and closed out Friday at a…

    Read more »

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    19 Jun 2024 $0.0098 0.00% Final 04 Jul 2024
    16 Jun 2023 $0.0069 0.00% Final 04 Jul 2023

    AFP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About AFT Pharmaceuticals Ltd

    AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includesthe sales and distribution activity relating to the Australian market.

    AFP Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    18 Jun 2024 $2.83 $0.02 0.71% 385 $2.83 $2.83 $2.83
    17 Jun 2024 $2.81 $0.01 0.36% 150 $2.81 $2.81 $2.81
    14 Jun 2024 $2.80 $0.00 0.00% 20,441 $2.80 $2.80 $2.79
    12 Jun 2024 $2.80 $-0.01 -0.36% 217 $2.80 $2.80 $2.80
    06 Jun 2024 $2.81 $0.01 0.36% 184 $2.81 $2.81 $2.81
    04 Jun 2024 $2.80 $0.00 0.00% 2,500 $2.82 $2.82 $2.80
    29 May 2024 $2.80 $-0.02 -0.71% 245 $2.84 $2.84 $2.80
    27 May 2024 $2.82 $0.01 0.36% 831 $2.90 $2.90 $2.82

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew Michael Lane Non-Executive Director Sep 2023
    Mr David Mark Flacks Non-Executive ChairmanNon-Executive Director Jun 2015
    Mr Flacks has a number of governance roles and has been chair of AFT since the company's initial public offer in 2015. David is also chair of the Suncorp New Zealand group of companies. He is a director of Todd Corporation, and several environmentally focused pro bono organisations. He is a former chair of the NZX Markets Disciplinary Tribunal and a former member of the Takeovers Panel. He is also a director of boutique corporate law firm Flacks & Wong. He was for many years a senior corporate partner at Bell Gully and was general counsel and company secretary of Carter Holt Harvey during the 1990s.

    Dr John Douglas Wilson Non-Executive Director Sep 2012
    Mr Wilson was a New Zealand physician and academic. He joined an International pharmaceutical company, Boehringer Ingelheim, working in their US subsidiary, becoming their Head of Medical Research and Regulatory Affairs, the interface with FDA, playing a role in steering 10 drugs through the FDA to the US and global markets. He moved to Head Office in Germany, being responsible for those same functions for worldwide drug development. He chaired the company's International Medical Committee overseeing the medical aspects of all drugs in development globally, and their Internal Labelling Committee for the drugs on the worldwide market. He was the medical parent of Spiriva, a drug for Chronic Obstructive Pulmonary Disease (COPD), one of the global killers. The drug last year sold $5 billion. He now consults internationally on new drugs in development, and for pharmaceutical companies.
    Ms Marree Atkinson Chief of StaffManaging Director Sep 2012
    Mrs Atkinson has been involved in all aspects of AFT's business since its establishment in 1997, including roles in sales, regulatory affairs, customer services and logistics. Her role as Chief of Staff sees her involved in the day-today running of AFT's head office including managing staffing requirements and special projects involving AFT's head and affiliate offices. She is a registered nurse previously practising at Waikato Hospital.

    Mr Hartley Atkinson FounderChief Executive OfficerExecutive Director Sep 1997
    Dr Atkinson founded AFT in 1997. Before founding AFT, Hartley worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to that Hartley was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital. He is the author of more than 30 scientific publications and his work has been published in the prestigious The New England Journal of Medicine.

    Ms Anita Baldauf Non-Executive Director Nov 2020
    Ms Baldauf joins AFT with a broad and international experience in FMCG and Corporate Finance. Her 22 year career at Nestle and L'Oreal (Laboratoires inneov), mostly as CFO in multiple developed and developing countries, gave her a rich expertise in finance and investor relation, compliance and governance, international business as well as people development, and value based leadership. Ms Baldauf is impassioned about driving impact, particularly in the area of Wellbeing and mental health. She is an EHF Fellow, where she is advising and supporting New Zealand and international start-ups and impact ventures as they navigate through the challenges of exponential change, rapid growth, and their aim for impact and sustainability.
    Dr Ted Witek Non-Executive Director Jan 2021
    Mr Witek served Boehringer Ingelheim Pharmaceuticals for nearly 25 years where he held various pharmacology and clinical research positions, including Director of Respiratory and Immunology Clinical Research leading to his roles as President and CEO of Boehringer Ingelheim's Canadian and Portuguese operations. He led the Global Operating Team for Spiriva serving as Co-Chair of the Global Alliance with Pfizer. Ted also was Chief Scientific Officer & Senior Vice President, Corporate Partnerships, at Innoviva (Formerly Theravance, Inc.). He also served on the Board of Directors of Canada's ResearchBased Pharmaceutical Companies (Rx&D) including Chair of the Health Technology Assessment and Public Relations Committee. He was appointed to the Ontario Health Innovation Council, an advisor to the Design for Health Program at OCAD University. He is currently an Adjunct Professor & Senior Fellow at the University of Toronto's School of Public Health & Leslie Dan Faculty of Pharmacy. He serves as Director of the DrPH program. Ted is the author of more than 100 scientific papers as well as several chapters and books.

    Mr Malcolm Tubby Chief Financial OfficerCompany Secretary
    Malcolm Tubby Chief Financial OfficerCompany Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hartley Atkinson & Colin Mckay 72,031,609 68.69%
    Accident Compensation Corporation 4,855,056 4.63%
    MMC Limited 2,900,650 2.77%
    Forsyth Barr Custodians Limited (i) 2,754,417 2.63%
    FNZ Custodians Limited (i) 2,611,622 2.49%
    BNP Paribas Nominees (Nz) Limited (i) 1,921,635 1.83%
    HSBC Nominees A/C 1,694,603 1.62%
    BNP Paribas Nominees (Nz) Limited 1,099,553 1.05%
    Hama Holdings Limited 867,826 0.83%
    New Zealand Depository Nominee Limited 664,489 0.63%
    Public Trust - Nzcsd 571,027 0.54%
    Custodial Services Limited 389,920 0.37%
    FNZ Custodians Limited (ii) 309,301 0.29%
    JP Morgan Nominees Australia Limited 300,000 0.29%
    Jbwere (Nz) Nominees Limited 258,000 0.25%
    Forsyth Barr Custodians Limited (ii) 233,900 0.22%
    Rivers One Limited 221,305 0.21%
    Hamish Stewart Atkinson & Karen Winifred Atkinson & Andrew John Marriott 203,333 0.19%
    Joeri Yvonne Jozef Sels 203,025 0.19%
    BNP Paribas Nominees (Nz) Limited (ii) 174,659 0.17%